JPRN-jRCT1031200329进行中（未招募）未知
Open-ravel randomized control trial to evaluate the efficacy of biologics for ulcerative colitis with treatment-refractoriness
aganuma Makoto0 个研究点目标入组 231 人开始时间: 2021年1月28日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 231
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients who meet the criteria of the ulcerative colitis diagnostic criteria (revised in 2018) of the Ministry of Health, Labor and Welfare Specified Disease or Intractable Inflammatory Intestinal Disorders Research Group
- •2) Patients with steroid resistance / dependence at the time of registration or who have previously received systemic steroids
- •3) Patients who have never used antiTNFa antibody preparations, ustekinumab, or vedolizumab
- •4) Patients with a Mayo score of 6 points or higher and an endoscopic Mayo score of 2 or higher at the time of registration (Endoscopic scores at the enrollment were assessed by local institutional endoscopists)
- •5) Patients who are 16 years of age or older at the time of obtaining consent and who have obtained written consent from the patient. For patients with age of 16-19, patients who have obtained the written consent of the person and the substitute
- •6) Those who have received sufficient explanation before participating in this study, and who have obtained the document for contents after sufficient explanations. For minors, those who have obtained the written consent of the person and the substitute
- •Definition of steroid resistance The failure to respond to systemic steroid treatment at a dose of 1 to 1.5mg per kg per day for 1 week.
- •Definition of steroid dependence Either an inability to reduce steroids below the equivalent dose of prednisolone 10 mg per day within 3 months of starting steroid therapy without recurrent active disease, or relapse within 3 months of cessation of steroid therapy.
排除标准
- •1) Patients classified as fulminant in the clinical severity classification
- •2) Patients who are suspected of having colitis rather than ulcerative colitis (infectious enteritis, etc.)
- •3) Patients with symptomatic gastrointestinal stricture
- •4) Patients who areplanning colectomy for UC
- •5) Pregnant women or patients who may be pregnant, lactating patients or those who wish to become pregnant during the study period
- •6) Patients with contraindications to use infliximab, ustekinumab, or vedolizumab in the package insert
- •7) Patients who the doctor in charge deems inappropriate to be included in this study
- •8) Patients participating in clinical trials of other medications
- •9) Excluding criteria for concomitant medication as below;
- •1 Patients who have increased the dose of oral 5-aminosalicylic acid within 2 weeks before the registration.
- •2 Patients who have newly started the enema or suppository treatment with 5-aminosalicylic acid or steroids within 1 week before the registration.
- •3 Patients receiving oral prednisolone (or equivalent corticosteroid) or intravenous corticosteroid in excess of 30 mg /day within 2 weeks before the registration. In addition, patients who are receiving 30mg daily dose or less of oral or intravenous corticosteroids and whose dosage is not constant within 2 weeks.
- •4 Patients who newly started thiopurine (azathioprine / 6-mercaptopurine) within 8 weeks before the registration. Patients whose dose of thiopurine was changed within 2 weeks before registration in patients who already received thiopurine.
- •5 Patients receiving cyclosporine or tacrolimus within 4 weeks before the registration.
- •6 Patients receiving carotegrastmethyl,upadacitinib,filgotinib or tofacitinib within a week before the registration.
- •7 Patients receiving apheresis therapy within 4 weeks before the registration. tofacitinib
研究者
相似试验
尚未招募
2 期
Apamargadi nasya in ArdhavbhedakCTRI/2022/03/041262DR YAMINI JAYENDRA GAWAND
尚未招募
3 期
The effect of Dashang Guggul in Medoroga(increased lipid levels).CTRI/2022/07/043754Dr Rinkal Mane
招募中
不适用
Open randomized controlled trial to evaluate efficacy of clindamycin in the pulmonary Mycobacterium avium complex diseasePulmonary Mycobacterium avium complex diseaseJPRN-UMIN000016615Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan100
已完成
不适用
An open-label randomized controlled trial to assess the efficacy and safety of chronic hepatitis C and compensated cirrhosis patients with the prescribing pattern of vitaminD plus peginterferon alpha-2a /ribavirin.Chronic hepatitisC patients and compensated cirrhosis patientsJPRN-UMIN000008342Saitama Medical University80
已完成
不适用
An open-label randomized controlled trial to assess the efficacy and safety of chronic hepatitis C patients with vitaminD plus peginterferon alpha-2a /ribavirin.versus alfacalcidol plus peginterferon alpha-2a /ribavirin.Chronic hepatitis C patients with genotype 1 and high viral load (>= 5 Log IU/mL)JPRN-UMIN000004210Saitama Medical University40